Next Article in Journal
VOCs Profiling and Quality Assessment of Milk Employing Odorant-Binding Proteins-Based Fluorescence Biosensor
Previous Article in Journal
Factor XII—A New Therapeutic Target? A Systematic Review
Previous Article in Special Issue
New Insights into Neuromuscular Junction Biology: Evidence from Human and Animal Research
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 27
Issue 3
10.3390/ijms27031332
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Macrophage Infiltration, Activation, and Therapeutic Implication in Skeletal Muscle Injury and Repair

by
Xingyu Wang
* and
Lan Zhou
Department of Neurology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2026, 27(3), 1332; https://doi.org/10.3390/ijms27031332
Submission received: 23 December 2025 / Revised: 26 January 2026 / Accepted: 27 January 2026 / Published: 29 January 2026
(This article belongs to the Special Issue Musculoskeletal Disorders: From Molecular Pathology to Novel Therapeutic Approach)
Browse Figures
Versions Notes

Abstract

Skeletal muscle injury triggers inflammatory response, of which the accumulation of intramuscular monocytes/macrophages is a prominent feature. Macrophages in injured muscle comprise both blood monocytes-derived infiltrating macrophages, which are recruited through CCR2 signaling, and pre-existing muscle resident macrophages, which are established during embryogenesis and maintained until adulthood through self-renewal proliferation. During regenerative acute muscle injury, infiltrating monocytes/macrophages are heterogeneously activated in a temporal dynamic, responding to the changing microenvironment in injured muscle and contributing to the complete injury repair. Injury-associated monocytes/macrophages recede with the completion of muscle injury repair. In contrast, injury-associated monocytes/macrophages persist in dystrophic muscle of Duchenne muscular dystrophy (DMD), likely accounting for persistent inflammation and progressive fibrosis of DMD muscle. We review here the current knowledge on monocyte/macrophage infiltration and activation in both acutely injured skeletal muscle and dystrophic muscle with subsequent discussion of the potential therapeutic implication in treating muscular dystrophy.

1. Introduction

The homeostasis of skeletal muscle can be compromised by various factors, such as acute injury, infection, genetic defects, and aging. The consequences differ based on the triggering factors. Acute injuries from trauma or myotoxin exposure are usually repairable. However, triggering factors, such as repeated injuries, large volumetric muscle loss, and chronic muscle injury caused by genetic defects, commonly result in fibrofatty tissue deposition, impairing muscle function. Successful skeletal muscle regeneration hinges on a highly coordinated process involving myofiber regeneration, inflammation, extracellular matrix (ECM) remodeling, and revascularization [1,2,3]. Myofiber regeneration depends on muscle resident myogenic stem cells, muscle satellite cells (MuSCs) [4,5], which are activated and differentiated in response to injury-induced changes in tissue microenvironment to rebuild myofibers [6,7,8,9]. Among all the environmental factors impacting myogenesis, macrophages have emerged to be crucial in regulating the quiescence, activation, and differentiation of MuSCs in a spatiotemporal manner [10,11].
Macrophages are multi-originated cells, exhibiting remarkable functional heterogeneity, including their active roles in maintaining tissue homeostasis and repairing injured muscle [12,13,14,15,16]. In the steady state, resident macrophages act as surveillance cells, maintaining tissue integrity. Following acute injury, macrophages are essential for regenerative repair. However, in chronic or degenerative conditions, macrophages can contribute to tissue pathology [15,16,17,18,19], making them a potential therapeutic target. Currently, the origins of intramuscular macrophages both at the steady and disease states, as well as the chemotactic mechanisms of macrophage infiltration in the disease state, have been comprehensively elucidated. The heterogenic activation of macrophages is well documented in both acutely and chronically injured skeletal muscles. We review here the current knowledge on macrophage infiltration and activation in both regenerative (acute) and degenerative (muscular dystrophy) skeletal muscle injury and discuss its potential therapeutic implications to treat muscular dystrophy.

2. The Origins of Intramuscular Macrophages: Resident and Infiltrating Macrophages

Tissue macrophages are categorized into two main types: resident macrophages and infiltrating inflammatory macrophages. Resident macrophages, which populate all adult tissues including skeletal muscle, are primarily established during embryonic development [20]. They originate from two embryonic sources: primitive yolk sac macrophages and, subsequently, fetal liver monocytes (fetal monocytes). Fetal monocytes eventually replace most yolk sac-derived macrophages in nearly all tissues, except for the brain [14,21,22,23,24,25,26,27,28]. These embryonic macrophages can maintain themselves into adulthood through self-renewal. In the adult tissues including skeletal muscle, resident macrophage populations are further contributed to by adult blood monocytes, which originate from bone marrow hematopoietic stem cells (HSCs) and circulate in the blood [20,29,30,31,32,33]. In contrast to the resident macrophages, infiltrating macrophages are derived exclusively from HSC-originated adult blood monocytes [34,35]. While resident macrophages can be found in both steady-state and injured tissues, infiltrating macrophages are differentiated from recruited blood monocytes in injured tissues.
Skeletal muscle resident macrophages have been identified and studied. In the steady-state skeletal muscle of adult mice, resident macrophages reside in interstitial tissue and can be identified as CD45+F4/80+CD64+ Ly6Clo cells [20]. Lineage-tracing studies show that these muscle resident macrophages mostly originate from fetal monocytes and adult bone marrow HSCs, with only a small percentage from primitive macrophages [20]. The HSC-originated resident macrophages increase in fraction with aging, suggesting a gradual replacement of the embryo-originated resident macrophages by the HSC-originated ones [20]. Further studies with flow cytometry (FACS) and single cell-based RNA sequencing (scRNAseq) analysis reveal that embryo-originated resident macrophages are mainly of CCR2-MHCIIloLyve1hi and adult HSC-originated resident macrophages are completely of CCR2+MHCIIhiLyve1lo [20]. These findings were confirmed by another study using parabiosis and single-cell transcriptome analysis, which identified similar muscle resident macrophage subtypes: self-renewal TIM4+Lyve1+CCR2- cells and blood replenished TIM4-Lyve1-CCR2+ cells [36]. Furthermore, a recent study identified similar resident macrophage subpopulations across different steady-state murine tissues including skeletal muscle based on the expression of Timd4, Lyve1, Folr2, and Ccr2 genes: (1) Timd4+ and/or Lyve1+ and/or Folr2+ (TLF+) self-renewal macrophages originated from yolk sac and fetal monocyte precursors; (2) TLF-Ccr2+ macrophages that can be entirely replaced by blood monocytes; and (3) TLF-Ccr2- macrophages which express a high level of MHCII molecules and receive a moderate contribution from adult monocytes [37]. These findings together strongly suggest that TLF expression primarily marks the embryo-derived resident macrophages and CCR2 and MHCII expression preferentially mark the adult monocytes-derived resident macrophages at least in steady-state murine tissues. The origins of adult skeletal muscle resident macrophages are summarized in Figure 1. Interestingly, scRNAseq analysis of human macrophages also indicated that the Lyve1+ macrophages overlap strongly with fetal liver macrophages while the Lyve1- macrophages expressed the monocyte signatures gene, suggesting embryonic and monocytic origins of Lyve1+ and Lyve1- macrophages, respectively [38]. It therefore suggests that human tissue resident macrophages may share similar phenotypes with murine ones.

3. Macrophage Infiltration Following Skeletal Muscle Injury

3.1. Blood Monocytes Consist of Two Subtypes

Infiltrating macrophages are derived exclusively from HSC-originated adult blood monocytes following tissue injury [34,35]. Murine blood monocytes consist of two principal subsets: Ly6ChiCCR2+CX3CR1lo inflammatory monocytes and Ly6CloCCR2-CX3CR1hi patrolling monocytes, distinguished by the expression of cell surface markers Ly6C, C-C motif chemokine receptor 2 (CCR2), and C-X3-C motif chemokine receptor 1 (CX3CR1) [39]. In humans, Ly6C is not expressed, and the CD14hiCD16lo and CD14lo CD16hi monocytes correspond to the Ly6Chi and Ly6Clo monocytes in mice, respectively [40].

3.2. Infiltrating Macrophages Are Derived from Ly6Chi, but Not Ly6Clo, Blood Monocytes in Both Acutely Injured and Dystrophic Skeletal Muscles

Following acute skeletal muscle injury, Ly6Chi inflammatory monocytes in blood circulation quickly migrate into injured muscles and differentiate into Ly6Chi inflammatory macrophages [39]. The spleen serves as an additional reservoir for these Ly6Chi monocytes, which can be mobilized to sites of inflammation including skeletal muscle [41,42]. This recruitment from the blood circulation depends on the chemokine system, where tissue cells release chemokine ligands that attract circulating cells bearing matching receptors. Specifically, the influx of Ly6Chi monocytes into acutely injured muscle requires CCR2 on the monocytes and its primary ligand, CCL2, which is produced by both resident muscle cells and infiltrating macrophages [43,44,45]. Impairing CCR2 or CCL2 expression reduces macrophage accumulation in various acute muscle injury models [35,43,44,45,46]. In contrast, Ly6Clo patrolling monocytes patrol the vascular endothelium and may enter tissues via CX3CR1/CX3CL1 signaling to contribute to resident macrophage populations [47]. But it has been shown that Ly6Clo monocytes are not recruited by acutely injured muscle during injury repair [48]. Despite that, Ly6Chi macrophages only dominate at day 1 post-injury, and Ly6Clo macrophages become the predominant intramuscular macrophage type at day 3 post-injury, following acute muscle injury [35,44]. This shift occurs because Ly6Chi inflammatory macrophages switch to a Ly6Clo state after phagocytosing necrotic muscle debris [35,49,50,51,52,53]. This Ly6Chi-to-Ly6Clo switch, rather than the pre-existing resident macrophages at steady state, is the major contribution to the Ly6Clo macrophages accumulated in injured muscle [35,53,54].
As seen in acutely injured skeletal muscles, accumulation of macrophages is also a prominent feature in chronically injured muscles of Duchenne muscular dystrophy (DMD) mouse model mdx [55]. Blood Ly6Chi monocytes are recruited into mdx muscles via CCR2 signaling [56,57]. Ly6Clo monocytes do not contribute to intramuscular macrophages in mdx mice, even in the absence of CCR2 signaling [58]. Intramuscular Ly6Clo macrophages in mdx muscles are also switched from Ly6Chi macrophages [56,57,58]. Lineage-tracing and scRNAseq studies have provided evidence that macrophages in the dystrophic mdx muscles are mostly HSCs-originated and blood monocytes-derived infiltrating macrophages and that embryo-originated resident macrophages barely expand and contribute minimally to the intramuscular macrophages in mdx muscles [58].

4. Pro-Regenerative Macrophage Activation in Acute Skeletal Muscle Injury and Repair

Macrophage activation has been extensively studied in mouse models of acute skeletal muscle injury, which can be induced by multiple approaches, such as mechanical damage, contusion, freeze, myotoxin or heavy metal salt injection, or ischemia, and these injuries lead to a similar repair process [59]. Acute skeletal muscle injury usually repairs within 2 to 3 weeks without significant residual deficits unless the injury is repeated [60] or with large volume of muscle loss [61,62]. In the barium chloride (BaCl2)-induced limb muscle injury, massive myofiber necrosis along with infiltration of inflammatory cells is seen early after injury, such as on day 1 post-injury. Around day 3 post-injury, necrotic myofibers largely disappear, while inflammatory cell infiltration reaches peak. On day 7 post-injury, inflammatory cell infiltration decreases compared to on day 3. Meanwhile, necrotic myofibers are completely gone, central-nucleated regenerating myofibers are massively present, and deposition of extracellular matrix is seen. On day 14 post-injury, inflammatory cell infiltration completely recedes, regenerated myofibers grow in size, and deposition of extracellular matrix largely decreases [44]. An adequate inflammatory response, featuring massive macrophage infiltration, is required for the complete muscle regeneration [1,63,64,65]. Both muscle resident macrophages and infiltrating macrophages are required in this regenerative skeletal muscle injury repair [10,35,36,43,44,45,46,66,67].

4.1. Temporal Dynamics and Heterogeneity of Macrophage Subpopulations During Acute Skeletal Muscle Injury Repair

The switch from Ly6Chi to Ly6Clo macrophages during skeletal muscle repair indicates significant shifts in activation status of these cells. Historically, Ly6Chi and Ly6Clo macrophage subpopulations were associated with the bipolar M1 (pro-inflammatory) and M2 (anti-inflammatory, pro-regenerative, or pro-fibrotic) classifications, respectively [68,69]. This phenotypic switch does coincide with a functional change from a pro-inflammatory to an anti-inflammatory state, as evidenced by the switches of pro- to anti-inflammatory gene expression [15,19,35,49,54,66,70,71,72] and pro- to anti-inflammatory lipid mediator production [73,74]. However, in vivo studies have strongly suggested that this M1/M2 dichotomy is over-simplified and insufficient to describe macrophage behavior in complex in vivo settings [68,75,76,77]. Macrophages are highly plastic and can rapidly adapt their function in response to the tissue microenvironment, resulting in diverse subtypes. Recent studies, particularly those with single cell-based transcriptome analysis, have revealed coexistence of heterogeneous macrophage subpopulations at various time points with dynamic change in proportions during acute skeletal muscle injury repair [78,79,80,81]. Early after injury (day 0.5 to 2), two monocyte/macrophage subpopulations predominate: one featuring the expression of genes resembling blood Ly6Chi monocytes and the other one featuring pro-inflammatory genes (i.e., Cxcl1, Cxcl3, Ccl2, Ccl6, Ccl7, Il1a, Il1b, and Cd14). Around day 3 post-injury, monocytes are still present, while the pro-inflammatory subpopulation disappears, along with emergence of two macrophage subpopulations: (1) Gpmnb+Spp1+ subpopulation featuring genes regulating ECM remodeling (i.e., Spp1, Fabp5, and Trem2) and muscle regeneration (i.e., Gpnmb, Igf1, and Gdf15); (2) interferon-responsive macrophage (IFNRM) subpopulation featuring high expressions of IFN-responsive genes (ISGs) such as Rsad2, Ifit1, Cxcl10, and Irf7. Day 3 post-injury also sees massive proliferation of macrophages. After day 3, monocytes, Gpmnb+Spp1+, and proliferating subpopulations recede over time, along with emergence of macrophage subpopulations featuring inflammation-resolution genes (i.e., Gpx3, Rgs2, Ccl8, and Mrc1) and resident macrophage genes (i.e., MHCII genes) [78,81] (Figure 2). The temporal dynamics of different monocyte/macrophage subpopulations correlate with the different stages of acute skeletal muscle injury and repair: (1) inflammatory subpopulation emerges along with massive myofiber damage at day 1; (2) massive macrophage proliferation is seen at the peak of inflammation at day 3; (3) Gpmnb+Spp1+ and IFNRM subpopulations emerge after starting the clearance of necrotic myofibers at day 3 and precede deposition of ECM and emergence of regenerating myofibers; (4) inflammation resolution subpopulations emerge along with recession of inflammation from day 3 to day 7; (5) Gpmnb+Spp1+ and IFNRM subpopulations recede after the emergence of massive regenerating myofibers at day 7 to day 14 [44,78,81] (Figure 2). These findings strongly suggest that the sequential appearance of specialized macrophage subpopulations may be critical for the proper muscle injury repair. In addition, none of these macrophage subpopulations conform to strict M1 or M2 activation status [81]. Both Ly6Chi and Ly6Clo populations are heterogeneous: monocytes, pro-inflammatory, and IFNRM subpopulations are Ly6Chi, which are more pro-inflammatory in general, while the other subpopulations are Ly6Clo, which are more anti-inflammatory in general [81].

4.2. Both Resident and Infiltrating Macrophages Play Pro-Regenerative Roles in Regulating Acute Skeletal Muscle Injury Repair

Following acute skeletal muscle injury, resident macrophage populations are quickly overwhelmed by the massively infiltrated blood monocytes-derived macrophage populations, and they account for only a minor fraction of intramuscular macrophages [81]. Despite the minor presence, a recent study indicated that resident macrophages play an indispensable role in acute skeletal muscle injury repair [36]. Depleting TIM4+Lyve1+ resident macrophages early in the acute injury repair process leads to an extended persistence of necrotic fibers and hinders muscle regeneration. Consequently, this self-renewing resident macrophage subtype is necessary for the efficient removal of damaged tissue to facilitate proper regeneration [36]. Indeed, single cell-based transcriptomic analysis revealed that TIM4+Lyve1+ resident macrophages upregulate genes related to phagocytosis and inflammatory cell recruitment post-injury, indicating a potential additional role in triggering the inflammatory response [36]. However, the depletion of this specific subset did not alter the influx of either neutrophils or monocytes [36], suggesting possible compensation by other resident cells.
Infiltrating macrophages spatiotemporally regulate key processes for complete repair after acute muscle injury, including inflammation, myogenesis, and ECM remodeling. Impairing the recruitment or timely phenotypic transition of infiltrating macrophages hinders muscle regeneration, which is often accompanied by deposition of fibrofatty tissue [10,35,43,44,45,46,66,67]. These observations imply that the resident macrophage population is unable to compensate for the roles of infiltrating macrophages to support complete repair of acutely injured skeletal muscle.
Infiltrating macrophages regulate both the propagation and the resolution of inflammatory response during acute muscle injury repair. scRNAseq analysis shows the presence of a pro-inflammatory macrophage subpopulation at an early stage, producing a high level of pro-inflammatory mediators, and inflammation-resolution macrophage subpopulations at a later stage, producing a high level of inflammation-resolution mediators after acute muscle injury [78,81]. In addition to producing inflammatory mediators, the early infiltrated Ly6Chi macrophages are also required to clear damaged muscle debris, as blocking macrophage infiltration by CCR2 deficiency delays the clearance of necrotic muscle fibers [44]. Phagocytosis of damaged tissue debris has been shown to drive the pro- to anti-inflammatory phenotype switch of macrophages [35,49,50,51,52,53].
Infiltrating macrophages regulate myofiber regeneration by orchestrating the activation, proliferation, differentiation, and fusion of myogenic cells post-injury. These functions appear to be distributed among distinct macrophage subtypes. Pro-inflammatory macrophages primarily enhance the activation and proliferation of myogenic cells, whereas anti-inflammatory macrophages support their differentiation and fusion [35,82,83,84]. An early study showed that conditioned media from pro-inflammatory activated, in vitro cultured macrophages greatly enhanced the proliferative potential of human primary myoblasts, indicating a role of soluble factors secreted by pro-inflammatory macrophages [85]. Subsequent studies further identified that pro-inflammatory macrophage-derived factors, including fibronectin [86], IL-6 [87], TNF-α [88], PGE2 [89], and A Disintegrin-Like and Metalloproteinase with Thrombospondin Type 1 Motif (ADAMTS1) [90], can stimulate MuSC activation and proliferation. In contrast, anti-inflammatory macrophages likely promote myoblast differentiation and myofiber growth through factors like IL-4 [91], IGF-1 [44,92,93], and GDF-3 [94]. Notably, the Gpnmb+Spp1+ macrophage subpopulation identified by scRNAseq analysis highly expresses pro-regenerative factors GDF-15 and GPNMB [79,95] and resides with regenerating myofibers [95], suggesting an important role of this macrophage subpopulation in myofiber regeneration. Additionally, the shift in macrophage phenotype during repair is associated with increased glutamine synthesis, which further enhances satellite cell activation and regeneration [96]. Therefore, the temporal dynamics of different macrophage phenotypes appear critical for proper muscle regeneration. This concept is supported by studies showing that disruption of key signaling molecules involved in macrophage phenotypic switching, including IGF-1 [93], Meteorin-like (Metrnl) [97], AMP-activated protein kinase-1 (AMPKα1) [49,98], Nuclear Factor IX (Nfix) [52], CCAAT/enhancer binding protein-β (C/EBPβ) [72], and peroxisome proliferator-activated receptor-γ (PPARγ) [94], impairs the regenerative process.
Infiltrating macrophages are key regulators of ECM remodeling during acute skeletal muscle injury repair. ECM remodeling is a tightly controlled process of temporary ECM deposition and degradation that provides crucial structural support for activating and differentiating myogenic cells. Beyond this scaffolding function, specific ECM components, including collagen 6a (Col6a) [99] and fibronectin [86], can directly activate muscle stem cells (MuSCs). The main producers of ECM are fibro/adipogenic progenitors (FAPs), which also aid myogenic cell activation and differentiation to promote regeneration [5,100,101,102]. However, when the repair process is disrupted, abnormal FAP activation can occur, leading to fibrofatty tissue accumulation and failure to support MuSC activation [102]. Macrophages modulate both the number and activity of FAPs in injured muscle. Pro-inflammatory macrophages secrete TNF-α to induce FAP apoptosis, thereby restricting excessive accumulation [103]. Conversely, anti-inflammatory macrophages can promote the proliferation of fibrogenic cells by producing pro-fibrotic factors such as TGF-β1 [104]. The scRNAseq-identified Gpnmb+Spp1+ macrophage subpopulation around day 3 post-acute injury features signature genes of scar-associated macrophages (SAMs) [81]. SAMs are found in multiple tissues and organs with physical proximity to excessive ECM, expressing genes regulating ECM deposition [105,106,107]. Therefore, Gpnmb+Spp1+ macrophages, aside from their potential role in myofiber regeneration, may also play an important role in ECM remodeling during acute skeletal muscle injury repair. Furthermore, depleting macrophages or inhibiting their recruitment not only hinders muscle regeneration but also promotes fibrosis [43,103], underscoring the essential role of infiltrating macrophages in controlling FAP behavior and ECM remodeling.
In summary, both resident macrophages and adequately infiltrated blood monocytes-derived infiltrating macrophages are critically required for proper acute skeletal muscle injury repair. Driven by the change of microenvironment in the injured muscle, infiltrating macrophages undergo temporal, heterogeneous activation and differentiate into functionally diverse subpopulations, which differentially regulate inflammation, myofiber regeneration, and ECM remodeling in a spatiotemporal manner.

5. Heterogeneous Macrophage Activation in Muscular Dystrophy

5.1. Duchenne Muscular Dystrophy (DMD)

Muscular dystrophies are a diverse group of genetic diseases characterized by progressive muscle atrophy and weakness [108], among which the most studied is Duchenne muscular dystrophy (DMD). DMD is caused by the defective dystrophin gene on the X chromosome [109], which disrupts the dystrophin–glycoprotein complex, leading to a fragile muscle cell membrane and subsequent muscle fiber deaths [110]. This genetic defect triggers a repeated cycle of muscle degeneration and regeneration, causing chronic inflammation and the replacement of muscle tissue with fibrous and fatty deposits [111]. DMD patients die prematurely from respiratory and cardiac muscle weakness [108,109]. Research on DMD primarily uses animal models, most commonly mdx mice. Mdx mice exhibit a less severe phenotype than human DMD patients [112,113,114,115]. In these mice, muscle inflammation begins around 3 weeks of age, continues until 2–3 months, and then gradually subsides in limb muscles but persists in the diaphragm [55,112,113,114,115]. Accordingly, progressive fibrosis develops in the diaphragm but not in the limb muscles. The progressive diaphragm fibrosis impairs respiratory muscle function in mdx mice, resembling the condition in human patients [55,114,116,117]. We will focus our following discussion on studies with mdx mice, as comprehensive study with DMD patient muscles is lacking.

5.2. Co-Existence of Heterogeneous Monocyte/Macrophage Subpopulations in mdx Muscles

Studies targeting macrophages in mdx muscles have generated controversial results. Depletion of macrophages at 4 weeks of age reduces limb muscle necrosis [118], likely due to reduced inflammation-induced muscle damage. Similarly, reduction of macrophage infiltration by germ-line deficiency of CCR2 in mdx mice decreases muscle damage and fibrosis while it improves muscle function in both limb muscle and diaphragm before 3 months of age [56,57]. Infiltrating Ly6Chi macrophages are also shown to contribute to the fibrosis of mdx leg muscles at 8 to 10 weeks of age by producing latent TGF-β1 [119]. On the other hand, an independent study depleting macrophages from mdx limb muscles at 10 to 12 weeks of age impairs myogenic cell proliferation and differentiation, decreases myofiber formation, and increases fibrofatty tissue deposition [120]. This controversy may be due to the different ages when macrophage depletion is performed, as the activation status of intramuscular macrophages in mdx muscles may vary in different ages.
Recent studies with single cell-based transcriptomic analysis and spatial transcriptomic analysis have revealed heterogeneous activation of macrophages underlying their pleotropic roles in mdx muscles [58,81,95,121,122]. Despite batch differences, these studies identified similar macrophage subpopulations: 1) pro-inflammatory monocyte/macrophage subpopulation; 2) pro-fibrotic/pro-regenerative Gpmnb+Spp1+ macrophage subpopulation; 3) IFN-activated macrophages; 4) macrophage populations resembling muscle resident macrophages; and 5) proliferating macrophages [58,81,95,121,122]. Data obtained from mdx limb muscles, including both early age (4 weeks) and older age (14 weeks), show that the pro-inflammatory monocytes/macrophages and Gpmnb+Spp1+ macrophages are the majority of intramuscular macrophages at 4 weeks [122], while resident-like macrophages are the majority at 14 weeks [81]. Comparative analysis among wild-type uninjured, acutely injured, and mdx muscles indicates that the pro-inflammatory monocytes/macrophages and Gpmnb+Spp1+ macrophages are injury-associated subpopulations that are present in injured, but not uninjured, muscles [81]. The predominance of these two monocyte/macrophage subpopulations in 4-week-old mdx limb muscle is therefore indicative of a high level of muscle damage. As blocking Ly6Chi monocytes infiltration by CCR2 deficiency reduces muscle damage [56,57], the highly pro-inflammatory monocytes/macrophages may also contribute to muscle damage at early age. Meanwhile, the pro-fibrotic/pro-regenerative Gpmnb+Spp1+ macrophages may be actively repairing the damaged myofibers. This speculation is supported by the study with spatial transcriptomics analysis, which shows multilayered regenerative inflammation zones where the pro-inflammatory monocytes/macrophages reside with necrotic myofibers while the Gpmnb+Spp1+ macrophages reside with regenerating myofibers [95]. In 14-week-old mdx mice, monocytes/macrophages contain similar subpopulations in the diaphragm compared to limb muscle, with a significantly higher fraction of pro-inflammatory monocytes/macrophages in the diaphragm than in limb muscle [58,81]. This finding suggests a higher degree of damage in the diaphragm than in limb muscle, possibly contributing to the persistent inflammation in mdx diaphragm.

5.3. The Persistence of Pro-Inflammatory Monocytes/Macrophages and Gpnmb+Spp1+ Macrophages May Contribute to Chronic Inflammation and Progressive Fibrosis in mdx Muscles

The direct comparison of monocytes/macrophages between acutely injured and mdx muscles did not identify distinct pathogenic monocyte/macrophage subpopulations in dystrophic muscle [81]. Instead, the injury-associated pro-inflammatory monocytes/macrophages and Gpnmb+Spp1+ macrophage subpopulations persist in dystrophic muscle but not in acutely injured muscle [78,81,95,122]. The persistence of these two subclusters, which reflects continuous monocyte infiltration and differentiation that is triggered by constant muscle injury in dystrophic muscle, may contribute to chronic inflammation and progressive fibrosis (Figure 2). The pro-inflammatory monocytes/macrophages may contribute to myofiber damage, which further induces inflammation. The Gpnmb+Spp1+ macrophages may also play an important role in fibrosis in addition to their potential roles in myofiber regeneration. This macrophage subpopulation features the expression of signature genes of SAMs, including Gpnmb, Spp1, Fabp5, Trem2, Cd9, and Cd63, which are reportedly associated with fibrogenesis across different tissues [105,106,107,123,124,125,126,127]. The Spp1 gene encodes osteopontin, which has been increasingly recognized for its involvement in the progression of tissue fibrosis [128]. Global genetic deletion of osteopontin in mdx mice leads to reduced intramuscular TGF-β, reduced fibrosis in the diaphragm, and increased muscle regeneration and strength [129]. Macrophage-specific deletion of Spp1 in mdx leads to reduction in an adipogenic stromal cell population, reduced intramuscular fat accumulation, and improved muscle function [130]. These in vivo findings support the notion that the Gpnmb+Spp1+ macrophages may contribute to the progressive fibrofatty tissue replacement in dystrophic muscle via, at least in part, the osteopontin expression. In line with this hypothesis, spatial transcriptome analysis has shown that the Gpnmb+Spp1+ macrophages are associated with stromal cells and ECM genes in the dystrophic muscle of mdx mice [122]. In addition to Spp1, macrophage-specific deletion of Trem2, another featured gene of Gpnmb+Spp1+ macrophages, has been reported to reduce fibrosis in mouse models of pulmonary fibrosis [131] and myocardial infarction [132]. These together add additional support to the potential fibrogenic roles of Gpnmb+Spp1+ macrophages in mdx muscles.

6. Suppressing Intramuscular Monocyte/Macrophage Accumulation as a Potential Therapy for DMD

Preclinical studies have demonstrated that ameliorating inflammation and fibrosis improves DMD muscle function [133,134,135,136,137,138,139]. Currently, the main therapeutic approach mitigating chronic inflammation and fibrosis in DMD is the use of glucocorticoids [140,141,142] (Table 1). The efficacy of these treatments has been shown to be limited, and chronic use of corticosteroids can lead to significant side effects, including reduced growth, weight gain, and osteoporosis [143,144]. Developing new pharmacotherapy to target inflammatory cells is needed. Monocytes/macrophages are the predominant inflammatory cells in mdx muscles [55]. The persistence of the injury-associated pro-inflammatory monocytes/macrophages and Gpnmb+Spp1+ macrophages in mdx muscles likely contribute to the pathological progression [78,81,95,122]. Therefore, targeting monocytes/macrophages may represent a viable approach to treat DMD.
Accumulation of monocytes/macrophages in mdx muscles mostly results from blood monocytes infiltration [58], which relies on CCR2 signaling [56,57]. Therefore, targeting CCR2 signaling may be viable to reduce the accumulation of monocytes/macrophages to alleviate the pathology of mdx muscles. Interestingly, CCR2 deficiency in mdx mice diminishes both Ly6Chi and Ly6Clo monocytes/macrophages in dystrophic muscles before 3 months of age, while it only diminishes Ly6Chi monocytes/macrophages, but not Ly6Clo macrophages, after 3 months. Correspondingly, the diaphragm pathology and function are improved at 3 months but not 6 months [56,57]. Thus, blocking Ly6Chi monocyte/macrophage infiltration via CCR2 deficiency does not provide a sustained improvement of mdx5cv diaphragm dystrophy. The beneficial effects are lost after the expansion of intramuscular Ly6Clo macrophages. A recently published study suggests that these expanded Ly6Clo macrophages are pathogenic [58]. They express a similar level of genes promoting inflammation and fibrosis, such as Ccl2, Tgfb1, Spp1, and Mmp14, compared to the infiltrating macrophages in age-matched mdx5cv muscles [58]. Moreover, the fraction of the pro-fibrotic Gpnmb+Spp1+ macrophages [105,122,123,124] in mdx5cv/Ccr2−/− muscles is similar to that in age-matched mdx5cv muscles [58]. Therefore, it appears necessary to suppress both Ly6Chi monocyte/macrophage infiltration and Ly6Clo macrophage expansion to achieve sustained reduction in macrophages and improvement in muscle dystrophy. To achieve this, the source of the Ly6Clo macrophage expansion in mdx5cv/Ccr2−/−muscles must be elucidated. In the same published study, the authors further provide evidence that the proliferation of pre-existing skeletal muscle resident macrophages, particularly those of embryonic origin, contributes to the Ly6Clo macrophage expansion when Ly6Chi monocyte/macrophage infiltration is blocked in mdx5cv/Ccr2−/− muscles [58]. Moreover, the proliferation of muscle resident macrophages in mdx5cv/Ccr2−/− muscles may be driven by an increased intramuscular level of colony-stimulating factor 1 (CSF1), which is mainly expressed by FAPs [58]. Consistently, it has been shown in an independent study that the FAP-derived CSF1 is required for the survival of self-renewing skeletal muscle resident macrophages [146]. Long-term inhibition of the CSF1 receptor (CSF1R) with pharmacological inhibitor effectively depletes muscle resident macrophages in mdx muscles [36]. However, no notable effect on myofiber size or diaphragm maximum tetanus force production is observed [36]. This is likely due to the compensation by blood monocytes-derived infiltrating macrophages, as it has been reported that CSF1R inhibition does not significantly impact blood monocytes [147] or monocyte-derived infiltrating macrophages [36,148]. Therefore, dual inhibition of CCR2 and CSF1R to suppress both the infiltration of inflammatory monocytes/macrophages and the pathogenic expansion of resident macrophages may be needed to persistently reduce the accumulation of intramuscular monocytes/macrophages to potentially provide sustained improvement of the pathology and function of DMD muscles.

7. Conclusions

In both acutely injured and dystrophic muscles, accumulation of monocytes/macrophages is a prominent feature of inflammation. Comprising both blood monocytes-derived infiltrating macrophages and pre-existing resident macrophages, intramuscular macrophages are heterogeneously activated in response to the microenvironment changes in injured muscles, regulating inflammation, myofiber regeneration, and ECM deposition. During the regenerative repair of acutely injured muscle, the heterogeneously activated monocyte/macrophage subpopulations are present in temporal dynamics, coordinating with the muscle injury repair process. In particular, the injury-associated monocyte/macrophage subpopulations recede along with the emergence of the inflammation resolution macrophage subpopulations. In contrast, the injury-associated monocyte/macrophage subpopulations persist in dystrophic DMD muscles where the muscle injury is chronic and secondary to genetic defects. This difference is likely the cause of the chronic inflammation and progressive fibrosis seen in dystrophic muscles but not in acutely injured muscles. Resident macrophages in the DMD mouse model undergo expansion and pathogenic activation when inflammatory monocyte infiltration is inhibited. While limiting myofiber damage by gene, cell, and pharmacological therapies represents a main treatment strategy, controlling persistent macrophage accumulation by dual suppression of inflammatory monocyte infiltration and resident macrophage expansion may provide a useful adjunct therapy for DMD. This hypothesis needs further testing.

Author Contributions

Writing—original draft preparation, X.W.; writing—review and editing, L.Z. and X.W.; funding acquisition, L.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number 1R01AR074428 (LZ).

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ADAMTS1A Disintegrin-Like and Metalloproteinase with Thrombospondin Type 1 Motif
AMPKα1AMP-activated protein kinase-1
CCL2CC motif chemokine ligand 2
CCR2CC motif chemokine receptor 2
C/EBPβCCAAT/enhancer binding protein-β
Col6aCollagen 6a
CSF1Colony-stimulating factor 1
CSF1RColony-stimulating factor 1 receptor
CX3CL1C-X3-C motif chemokine ligand 1
CX3CR1C-X3-C motif chemokine receptor 1
DMDDuchenne muscular dystrophy
ECMExtracellular matrix
FACSFlow cytometry analysis
FAPsFibro/adipogenic progenitors
GDF-3Growth differentiation factor-3
GDF-15Growth differentiation factor-15
GPNMBGlycoprotein nonmetastatic melanoma protein B
HSCsHematopoietic stem cells
IFNRMInterferon-responsive macrophages
IGF-1Insulin-like growth factor-1
IL-4Interleukin-4
IL-6Interleukin-6
ISGsIFN-responsive genes
Ly6CLymphocyte antigen 6 complex locus C
MetrnlMeteorin-like
MHCIIMajor histocompatibility complex class II
MuSCsMuscle satellite cells
NfixNuclear Factor IX
PGE2Prostaglandin E2
PPARγPeroxisome proliferator-activated receptor-gamma
SAMsScar-associated macrophages
scRNAseqSingle cell-based RNA sequencing
TGF-β1Transforming growth factor-beta 1
TIM4T-cell immunoglobulin and mucin domain containing 4
TLFTimd4 and/or Lyve1 and/or Folr2
TNF-αTumor necrosis factor-alpha

References

  1. Yin, H.; Price, F.; Rudnicki, M.A. Satellite cells and the muscle stem cell niche. Physiol. Rev. 2013, 93, 23–67. [Google Scholar] [CrossRef] [PubMed]
  2. Dumont, N.A.; Bentzinger, C.F.; Sincennes, M.C.; Rudnicki, M.A. Satellite Cells and Skeletal Muscle Regeneration. Compr. Physiol. 2015, 5, 1027–1059. [Google Scholar] [CrossRef]
  3. Bentzinger, C.F.; Wang, Y.X.; A Dumont, N.; A Rudnicki, M. Cellular dynamics in the muscle satellite cell niche. EMBO Rep. 2013, 14, 1062–1072. [Google Scholar] [CrossRef]
  4. Mauro, A. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 1961, 9, 493–495. [Google Scholar] [CrossRef]
  5. Murphy, M.M.; Lawson, J.A.; Mathew, S.J.; Hutcheson, D.A.; Kardon, G. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development 2011, 138, 3625–3637. [Google Scholar] [CrossRef]
  6. Wang, Y.X.; Rudnicki, M.A. Satellite cells, the engines of muscle repair. Nat. Rev. Mol. Cell Biol. 2011, 13, 127–133. [Google Scholar] [CrossRef]
  7. Dumont, N.A.; Wang, Y.X.; Rudnicki, M.A. Intrinsic and extrinsic mechanisms regulating satellite cell function. Development 2015, 142, 1572–1581. [Google Scholar] [CrossRef]
  8. Sousa-Victor, P.; García-Prat, L.; Muñoz-Cánoves, P. Control of satellite cell function in muscle regeneration and its disruption in ageing. Nat. Rev. Mol. Cell Biol. 2022, 23, 204–226. [Google Scholar] [CrossRef] [PubMed]
  9. Mashinchian, O.; Pisconti, A.; Le Moal, E.; Bentzinger, C.F. The Muscle Stem Cell Niche in Health and Disease. Curr. Top Dev. Biol. 2018, 126, 23–65. [Google Scholar] [CrossRef] [PubMed]
  10. Dort, J.; Fabre, P.; Molina, T.; Dumont, N.A. Macrophages Are Key Regulators of Stem Cells during Skeletal Muscle Regeneration and Diseases. Stem Cells Int. 2019, 4761427. [Google Scholar] [CrossRef]
  11. Wang, X.; Zhou, L. The multifaceted role of macrophages in homeostatic and injured skeletal muscle. Front. Immunol. 2023, 14, 1274816. [Google Scholar] [CrossRef]
  12. Wynn, T.A.; Chawla, A.; Pollard, J.W. Macrophages biology in development, homeostasis and disease. Nature 2013, 496, 445–455. [Google Scholar] [CrossRef]
  13. Kierdorf, K.; Prinz, M.; Geissmann, F.; Perdiguero, E.G. Development and function of tissue resident macrophages in mice. Semin. Immunol. 2015, 27, 369–378. [Google Scholar] [CrossRef]
  14. Hashimoto, D.; Chow, A.; Noizat, C.; Teo, P.; Beasley, M.B.; Leboeuf, M.; Becker, C.D.; See, P.; Price, J.; Lucas, D.; et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013, 38, 792–804. [Google Scholar] [CrossRef]
  15. Wynn, T.A.; Vannella, K.M. Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity 2016, 44, 450–462. [Google Scholar] [CrossRef]
  16. Ginhoux, F.; Schultze, J.L.; Murray, P.J.; Ochando, J.; Biswas, S.K. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat. Immunol. 2016, 17, 34–40. [Google Scholar] [CrossRef]
  17. McNelis, J.C.; Olefsky, J.M. Macrophages, immunity, and metabolic disease. Immunity 2014, 41, 36–48. [Google Scholar] [CrossRef] [PubMed]
  18. Noy, R.; Pollard, J.W. Tumor-associated macrophages: From mechanisms to therapy. Immunity 2014, 41, 49–61, Erratum in Immunity, 2014, 41, 866. [Google Scholar] [CrossRef] [PubMed]
  19. Vannella, K.M.; Wynn, T.A. Mechanisms of Organ Injury and Repair by Macrophages. Annu. Rev. Physiol. 2017, 79, 593–617. [Google Scholar] [CrossRef] [PubMed]
  20. Wang, X.; Sathe, A.A.; Smith, G.R.; Ruf-Zamojski, F.; Nair, V.; Lavine, K.J.; Xing, C.; Sealfon, S.C.; Zhou, L. Heterogeneous origins and functions of mouse skeletal muscle-resident macrophages. Proc. Natl. Acad. Sci. USA 2020, 117, 20729–20740. [Google Scholar] [CrossRef]
  21. Hoeffel, G.; Ginhoux, F. Fetal monocytes and the origins of tissue-resident macrophages. Cell. Immunol. 2018, 330, 5–15. [Google Scholar] [CrossRef]
  22. Hoeffel, G.; Ginhoux, F. Ontogeny of Tissue-Resident Macrophages. Front. Immunol. 2015, 6, 486. [Google Scholar] [CrossRef]
  23. Ginhoux, F.; Jung, S. Monocytes and macrophages: Developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 2014, 14, 392–404. [Google Scholar] [CrossRef] [PubMed]
  24. Gomez Perdiguero, E.; Klapproth, K.; Schulz, C.; Busch, K.; Azzoni, E.; Crozet, L.; Garner, H.; Trouillet, C.; de Bruijn, M.F.; Geissmann, F.; et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2015, 518, 547–551. [Google Scholar] [CrossRef] [PubMed]
  25. Mass, E.; Ballesteros, I.; Farlik, M.; Halbritter, F.; Günther, P.; Crozet, L.; Jacome-Galarza, C.E.; Händler, K.; Klughammer, J.; Kobayashi, Y.; et al. Specification of tissue-resident macrophages during organogenesis. Science 2016, 353, aaf4238. [Google Scholar] [CrossRef] [PubMed]
  26. Schulz, C.; Gomez Perdiguero, E.; Chorro, L.; Szabo-Rogers, H.; Cagnard, N.; Kierdorf, K.; Prinz, M.; Wu, B.; Jacobsen, S.E.W.; Pollard, J.W.; et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336, 86–90. [Google Scholar] [CrossRef]
  27. Hoeffel, G.; Chen, J.; Lavin, Y.; Low, D.; Almeida, F.F.; See, P.; Beaudin, A.E.; Lum, J.; Low, I.; Forsberg, E.C.; et al. C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 2015, 42, 665–678. [Google Scholar] [CrossRef]
  28. Ginhoux, F.; Greter, M.; Leboeuf, M.; Nandi, S.; See, P.; Gokhan, S.; Mehler, M.F.; Conway, S.J.; Ng, L.G.; Stanley, E.R.; et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330, 841–845. [Google Scholar] [CrossRef]
  29. Bain, C.C.; Bravo-Blas, A.; Scott, C.L.; Perdiguero, E.G.; Geissmann, F.; Henri, S.; Malissen, B.; Osborne, L.C.; Artis, D.; Mowat, A.M. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 2014, 15, 929–937, Erratum in Nat. Immunol. 2014, 15, 1090. [Google Scholar] [CrossRef]
  30. Epelman, S.; Lavine, K.J.; Beaudin, A.E.; Sojka, D.K.; Carrero, J.A.; Calderon, B.; Brija, T.; Gautier, E.L.; Ivanov, S.; Satpathy, A.T.; et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 2014, 40, 91–104. [Google Scholar] [CrossRef]
  31. Bain, C.C.; Hawley, C.A.; Garner, H.; Scott, C.L.; Schridde, A.; Steers, N.J.; Mack, M.; Joshi, A.; Guilliams, M.; Mowat, A.M.I.; et al. Long-lived self-renewing bone marrow-derived macrophages displace embryo-derived cells to inhabit adult serous cavities. Nat. Commun. 2016, 7, ncomms11852. [Google Scholar] [CrossRef]
  32. Tamoutounour, S.; Guilliams, M.; Sanchis, F.M.; Liu, H.; Terhorst, D.; Malosse, C.; Pollet, E.; Ardouin, L.; Luche, H.; Sanchez, C.; et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity 2013, 39, 925–938. [Google Scholar] [CrossRef]
  33. Scott, C.L.; Zheng, F.; De Baetselier, P.; Martens, L.; Saeys, Y.; De Prijck, S.; Lippens, S.; Abels, C.; Schoonooghe, S.; Raes, G.; et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat. Commun. 2016, 7, 10321. [Google Scholar] [CrossRef]
  34. Shi, C.; Pamer, E.G. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 2011, 11, 762–774. [Google Scholar] [CrossRef]
  35. Arnold, L.; Henry, A.; Poron, F.; Baba-Amer, Y.; van Rooijen, N.; Plonquet, A.; Gherardi, R.K.; Chazaud, B. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J. Exp. Med. 2007, 204, 1057–1069. [Google Scholar] [CrossRef] [PubMed]
  36. Babaeijandaghi, F.; Cheng, R.; Kajabadi, N.; Soliman, H.; Chang, C.-K.; Smandych, J.; Tung, L.W.; Long, R.; Ghassemi, A.; Rossi, F.M.V. Metabolic reprogramming of skeletal muscle by resident macrophages points to CSF1R inhibitors as muscular dystrophy therapeutics. Sci. Transl. Med. 2022, 14, eabg7504. [Google Scholar] [CrossRef] [PubMed]
  37. Dick, S.A.; Wong, A.; Hamidzada, H.; Nejat, S.; Nechanitzky, R.; Vohra, S.; Mueller, B.; Zaman, R.; Kantores, C.; Aronoff, L.; et al. Three tissue resident macrophage subsets coexist across organs with conserved origins and life cycles. Sci. Immunol. 2022, 7, eabf7777. [Google Scholar] [CrossRef]
  38. Mulder, K.; Patel, A.A.; Kong, W.T.; Piot, C.; Halitzki, E.; Dunsmore, G.; Khalilnezhad, S.; Irac, S.E.; Dubuisson, A.; Chevrier, M.; et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 2021, 54, 1883–1900.e1885. [Google Scholar] [CrossRef]
  39. Geissmann, F.; Jung, S.; Littman, D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19, 71–82. [Google Scholar] [CrossRef] [PubMed]
  40. Ziegler-Heitbrock, L.; Ancuta, P.; Crowe, S.; Dalod, M.; Grau, V.; Hart, D.N.; Leenen, P.J.M.; Liu, Y.-J.; MacPherson, G.; Randolph, G.J.; et al. Nomenclature of Monocytes and Dendritic Cells in Blood. Blood 2010, 116, e74–e80. [Google Scholar] [CrossRef]
  41. Swirski, F.K.; Nahrendorf, M.; Etzrodt, M.; Wildgruber, M.; Cortez-Retamozo, V.; Panizzi, P.; Figueiredo, J.-L.; Kohler, R.H.; Chudnovskiy, A.; Waterman, P.; et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009, 325, 612–616. [Google Scholar] [CrossRef] [PubMed]
  42. Rizzo, G.; Di Maggio, R.; Benedetti, A.; Morroni, J.; Bouche, M.; Lozanoska-Ochser, B. Splenic Ly6Chi monocytes are critical players in dystrophic muscle injury and repair. JCI Insight 2020, 5, e130807. [Google Scholar] [CrossRef]
  43. Lu, H.; Huang, D.; Ransohoff, R.M.; Zhou, L. Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair. FASEB J. 2011, 25, 3344–3355. [Google Scholar] [CrossRef]
  44. Lu, H.; Huang, D.; Saederup, N.; Charo, I.F.; Ransohoff, R.M.; Zhou, L. Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury. FASEB J. 2011, 25, 358–369. [Google Scholar] [CrossRef]
  45. Sun, D.; Martinez, C.O.; Ochoa, O.; Ruiz-Willhite, L.; Bonilla, J.R.; Centonze, V.E.; Waite, L.L.; Michalek, J.E.; McManus, L.M.; Shireman, P.K. Bone marrow-derived cell regulation of skeletal muscle regeneration. FASEB J. 2009, 23, 382–395. [Google Scholar] [CrossRef] [PubMed]
  46. Contreras-Shannon, V.; Ochoa, O.; Reyes-Reyna, S.M.; Sun, D.; Michalek, J.E.; Kuziel, W.A.; McManus, L.M.; Shireman, P.K. Fat accumulation with altered inflammation and regeneration in skeletal muscle of CCR2−/− mice following ischemic injury. Am. J. Physiol. Cell. Physiol. 2007, 292, C953–C967. [Google Scholar] [CrossRef] [PubMed]
  47. Auffray, C.; Fogg, D.; Garfa, M.; Elain, G.; Join-Lambert, O.; Kayal, S.; Sarnacki, S.; Cumano, A.; Lauvau, G.; Geissmann, F. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007, 317, 666–670. [Google Scholar] [CrossRef]
  48. Varga, T.; Mounier, R.; Gogolak, P.; Poliska, S.; Chazaud, B.; Nagy, L. Tissue LyC6− macrophages are generated in the absence of circulating LyC6− monocytes and Nur77 in a model of muscle regeneration. J. Immunol. 2013, 191, 5695–5701. [Google Scholar] [CrossRef]
  49. Mounier, R.; Théret, M.; Arnold, L.; Cuvellier, S.; Bultot, L.; Göransson, O.; Sanz, N.; Ferry, A.; Sakamoto, K.; Foretz, M.; et al. AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 2013, 18, 251–264. [Google Scholar] [CrossRef]
  50. Xiao, Y.Q.; Freire-De-Lima, C.G.; Schiemann, W.P.; Bratton, D.L.; Vandivier, R.W.; Henson, P.M. Transcriptional and translational regulation of TGF-β production in response to apoptotic cells. J. Immunol. 2008, 181, 3575–3585. [Google Scholar] [CrossRef]
  51. Johann, A.M.; Barra, V.; Kuhn, A.; Weigert, A.; von Knethen, A.; Brüne, B. Apoptotic cells induce arginase II in macrophages, thereby attenuating NO production. FASEB J. 2007, 21, 2704–2712. [Google Scholar] [CrossRef] [PubMed]
  52. Saclier, M.; Lapi, M.; Bonfanti, C.; Rossi, G.; Antonini, S.; Messina, G. The Transcription Factor Nfix Requires RhoA-ROCK1 Dependent Phagocytosis to Mediate Macrophage Skewing during Skeletal Muscle Regeneration. Cells 2020, 9, 708. [Google Scholar] [CrossRef]
  53. Zhang, J.; Qu, C.; Li, T.; Cui, W.; Wang, X.; Du, J. Phagocytosis mediated by scavenger receptor class BI promotes macrophage transition during skeletal muscle regeneration. J. Biol. Chem. 2019, 294, 15672–15685, Erratum in J. Biol. Chem. 2023, 299, 102942. [Google Scholar] [CrossRef]
  54. Wang, X.; Zhao, W.; Ransohoff, R.M.; Zhou, L. Infiltrating macrophages are broadly activated at the early stage to support acute skeletal muscle injury repair. J. Neuroimmunol. 2018, 317, 55–66. [Google Scholar] [CrossRef]
  55. Zhou, L.; Porter, J.D.; Cheng, G.; Gong, B.; Hatala, D.A.; Merriam, A.P.; Zhou, X.; Rafael, J.A.; Kaminski, H.J. Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice. Neuromuscul. Disord. 2006, 16, 32–38. [Google Scholar] [CrossRef]
  56. Mojumdar, K.; Liang, F.; Giordano, C.; Lemaire, C.; Danialou, G.; Okazaki, T.; Bourdon, J.; Rafei, M.; Galipeau, J.; Divangahi, M.; et al. Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR 2. EMBO Mol. Med. 2014, 6, 1476–1492. [Google Scholar] [CrossRef]
  57. Zhao, W.; Wang, X.; Ransohoff, R.M.; Zhou, L. CCR2 deficiency does not provide sustained improvement of muscular dystrophy in mdx 5cv mice. FASEB J. 2017, 31, 35–46. [Google Scholar] [CrossRef]
  58. Wang, Y.; Wang, X.; Alabdullatif, S.; Homma, S.T.; Alekseyev, Y.O.; Zhou, L. Expansion and pathogenic activation of skeletal muscle–resident macrophages in mdx5cv/Ccr2−/− mice. Proc. Natl. Acad. Sci. USA 2025, 122, e2410095122. [Google Scholar] [CrossRef] [PubMed]
  59. Baghdadi, M.B.; Tajbakhsh, S. Regulation and phylogeny of skeletal muscle regeneration. Dev. Biol. 2018, 433, 200–209. [Google Scholar] [CrossRef] [PubMed]
  60. Dadgar, S.; Wang, Z.; Johnston, H.; Kesari, A.; Nagaraju, K.; Chen, Y.-W.; Hill, D.A.; Partridge, T.A.; Giri, M.; Freishtat, R.J.; et al. Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. J. Cell Biol. 2014, 207, 139–158. [Google Scholar] [CrossRef]
  61. Grogan, B.F.; Hsu, J.R. Skeletal Trauma Research, C. Volumetric Muscle Loss. J. Am. Acad. Orthop. Surg. 2011, 19, S35–S37. [Google Scholar] [CrossRef]
  62. Corona, B.T.; Rivera, J.C.; Owens, J.G.; Wenke, J.C.; Rathbone, C.R. Volumetric muscle loss leads to permanent disability following extremity trauma. J. Rehabil. Res. Dev. 2015, 52, 785–792. [Google Scholar] [CrossRef]
  63. Tidball, J.G.; Villalta, S.A. Regulatory interactions between muscle and the immune system during muscle regeneration. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 298, R1173–R1187. [Google Scholar] [CrossRef] [PubMed]
  64. Tidball, J.G. Mechanisms of muscle injury, repair, and regeneration. Compr. Physiol. 2011, 1, 2029–2062. [Google Scholar] [CrossRef]
  65. Wang, X.; Zhou, L. The Many Roles of Macrophages in Skeletal Muscle Injury and Repair. Front. Cell Dev. Biol. 2022, 10, 952249. [Google Scholar] [CrossRef]
  66. Wang, H.; Melton, D.W.; Porter, L.; Sarwar, Z.U.; McManus, L.M.; Shireman, P.K. Altered macrophage phenotype transition impairs skeletal muscle regeneration. Am. J. Pathol. 2014, 184, 1167–1184. [Google Scholar] [CrossRef]
  67. Liu, X.; Liu, Y.; Zhao, L.; Zeng, Z.; Xiao, W.; Chen, P. Macrophage depletion impairs skeletal muscle regeneration: The roles of regulatory factors for muscle regeneration. Cell Biol. Int. 2017, 41, 228–238. [Google Scholar] [CrossRef] [PubMed]
  68. Martinez, F.O.; Gordon, S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep. 2014, 6, 13. [Google Scholar] [CrossRef]
  69. Martinez, F.O.; Gordon, S.; Locati, M.; Mantovani, A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression. J. Immunol. 2006, 177, 7303–7311. [Google Scholar] [CrossRef] [PubMed]
  70. Perdiguero, E.; Sousa-Victor, P.; Ruiz-Bonilla, V.; Jardí, M.; Caelles, C.; Serrano, A.L.; Muñoz-Cánoves, P. p38/MKP-1–regulated AKT coordinates macrophage transitions and resolution of inflammation during tissue repair. J. Cell Biol. 2011, 195, 307–322. [Google Scholar] [CrossRef]
  71. Serhan, C.N.; Savill, J. Resolution of inflammation: The beginning programs the end. Nat. Immunol. 2005, 6, 1191–1197. [Google Scholar] [CrossRef]
  72. Ruffell, D.; Mourkioti, F.; Gambardella, A.; Kirstetter, P.; Lopez, R.G.; Rosenthal, N.; Nerlov, C. A CREB-C/EBPβ cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc. Natl. Acad. Sci. USA 2009, 106, 17475–17480. [Google Scholar] [CrossRef]
  73. Scher, J.U.; Pillinger, M.H. 15d-PGJ2: The anti-inflammatory prostaglandin? Clin. Immunol. 2005, 114, 100–109. [Google Scholar] [CrossRef]
  74. Giannakis, N.; Sansbury, B.E.; Patsalos, A.; Hays, T.T.; Riley, C.O.; Han, X.; Spite, M.; Nagy, L. Dynamic changes to lipid mediators support transitions among macrophage subtypes during muscle regeneration. Nat. Immunol. 2019, 20, 626–636, Erratum in Nat. Immunol. 2019, 20, 765–767. [Google Scholar] [CrossRef]
  75. Murray, P.J.; Allen, J.E.; Biswas, S.K.; Fisher, E.A.; Gilroy, D.W.; Goerdt, S.; Gordon, S.; Hamilton, J.A.; Ivashkiv, L.B.; Lawrence, T.; et al. Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity 2014, 41, 14–20. [Google Scholar] [CrossRef]
  76. Ransohoff, R.M. A polarizing question: Do M1 and M2 microglia exist? Nat. Neurosci. 2016, 19, 987–991. [Google Scholar] [CrossRef] [PubMed]
  77. Varga, T.; Mounier, R.; Horvath, A.; Cuvellier, S.; Dumont, F.; Poliska, S.; Ardjoune, H.; Juban, G.; Nagy, L.; Chazaud, B. Highly Dynamic Transcriptional Signature of Distinct Macrophage Subsets during Sterile Inflammation, Resolution, and Tissue Repair. J. Immunol. 2016, 196, 4771–4782. [Google Scholar] [CrossRef] [PubMed]
  78. Oprescu, S.N.; Yue, F.; Qiu, J.; Brito, L.F.; Kuang, S. Temporal Dynamics and Heterogeneity of Cell Populations during Skeletal Muscle Regeneration. iScience 2020, 23, 100993. [Google Scholar] [CrossRef] [PubMed]
  79. Patsalos, A.; Halasz, L.; Medina-Serpas, M.A.; Berger, W.K.; Daniel, B.; Tzerpos, P.; Kiss, M.; Nagy, G.; Fischer, C.; Simandi, Z.; et al. A growth factor–expressing macrophage subpopulation orchestrates regenerative inflammation via GDF-15. J. Exp. Med. 2022, 219, e20210420. [Google Scholar] [CrossRef]
  80. Sousa, N.S.; Bica, M.; Brás, M.F.; Sousa, A.C.; Antunes, I.B.; Encarnação, I.A.; Costa, T.M.; Martins, I.B.; Barbosa-Morais, N.L.; Sousa-Victor, P.; et al. The immune landscape of murine skeletal muscle regeneration and aging. Cell Rep. 2024, 43, 114975. [Google Scholar] [CrossRef]
  81. Wang, X.; Moy, J.K.; Wang, Y.; Smith, G.R.; Ruf-Zamojski, F.; Przytycki, P.F.; Sealfon, S.C.; Zhou, L. Heterogeneous Macrophage Activation in Acute Skeletal Muscle Sterile Injury and mdx5cv Model of Muscular Dystrophy. Int. J. Mol. Sci. 2025, 26, 8098. [Google Scholar] [CrossRef] [PubMed]
  82. Saclier, M.; Yacoub-Youssef, H.; Mackey, A.L.; Arnold, L.; Ardjoune, H.; Magnan, M.; Sailhan, F.; Chelly, J.; Pavlath, G.K.; Mounier, R.; et al. Differentially Activated Macrophages Orchestrate Myogenic Precursor Cell Fate During Human Skeletal Muscle Regeneration. Stem Cells 2013, 31, 384–396. [Google Scholar] [CrossRef] [PubMed]
  83. Hsieh, P.-L.; Rybalko, V.; Baker, A.B.; Suggs, L.J.; Farrar, R.P. Recruitment and therapeutic application of macrophages in skeletal muscles after hind limb ischemia. J. Vasc. Surg. 2018, 67, 1908–1920.e1. [Google Scholar] [CrossRef]
  84. Bencze, M.; Negroni, E.; Vallese, D.; Yacoub-Youssef, H.; Chaouch, S.; Wolff, A.; Aamiri, A.; Di Santo, J.P.; Chazaud, B.; Butler-Browne, G.; et al. Proinflammatory macrophages enhance the regenerative capacity of human myoblasts by modifying their kinetics of proliferation and differentiation. Mol. Ther. 2012, 20, 2168–2179. [Google Scholar] [CrossRef]
  85. Cantini, M.; Giurisato, E.; Radu, C.; Tiozzo, S.; Pampinella, F.; Senigaglia, D.; Zaniolo, G.; Mazzoleni, F.; Vitiello, L. Macrophage-secreted myogenic factors: A promising tool for greatly enhancing the proliferative capacity of myoblasts in vitro and in vivo. Neurol. Sci. 2002, 23, 189–194. [Google Scholar] [CrossRef]
  86. Bentzinger, C.F.; Wang, Y.X.; von Maltzahn, J.; Soleimani, V.D.; Yin, H.; Rudnicki, M.A. Fibronectin regulates Wnt7a signaling and satellite cell expansion. Cell Stem Cell 2013, 12, 75–87. [Google Scholar] [CrossRef]
  87. Zhang, C.; Li, Y.; Wu, Y.; Wang, L.; Wang, X.; Du, J. Interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast proliferation during muscle regeneration. J. Biol. Chem. 2013, 288, 1489–1499. [Google Scholar] [CrossRef]
  88. Li, Y.-P. TNF-α is a mitogen in skeletal muscle. Am. J. Physiol. Physiol. Cell. 2002, 285, C370–C376. [Google Scholar] [CrossRef]
  89. Ho, A.T.V.; Palla, A.R.; Blake, M.R.; Yucel, N.D.; Wang, Y.X.; Magnusson, K.E.G.; Holbrook, C.A.; Kraft, P.E.; Delp, S.L.; Blau, H.M. Prostaglandin E2 is essential for efficacious skeletal muscle stem-cell function, augmenting regeneration and strength. Proc. Natl. Acad. Sci. USA 2017, 114, 6675–6684. [Google Scholar] [CrossRef] [PubMed]
  90. Du, H.; Shih, C.-H.; Wosczyna, M.N.; Mueller, A.A.; Cho, J.; Aggarwal, A.; Rando, T.A.; Feldman, B.J. Macrophage-released ADAMTS1 promotes muscle stem cell activation. Nat. Commun. 2017, 8, 669. [Google Scholar] [CrossRef]
  91. Horsley, V.; Jansen, K.M.; Mills, S.T.; Pavlath, G.K. IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 2003, 113, 483–494. [Google Scholar] [CrossRef]
  92. Dumont, N.; Frenette, J. Macrophages protect against muscle atrophy and promote muscle recovery in vivo and in vitro: A mechanism partly dependent on the insulin-like growth factor-1 signaling molecule. Am. J. Pathol. 2010, 176, 2228–2235. [Google Scholar] [CrossRef]
  93. Tonkin, J.; Temmerman, L.; Sampson, R.D.; Gallego-Colon, E.; Barberi, L.; Bilbao, D.; Schneider, M.D.; Musarò, A.; Rosenthal, N. Monocyte/Macrophage-derived IGF-1 Orchestrates Murine Skeletal Muscle Regeneration and Modulates Autocrine Polarization. Mol. Ther. 2015, 23, 1189–1200. [Google Scholar] [CrossRef] [PubMed]
  94. Varga, T.; Mounier, R.; Patsalos, A.; Gogolák, P.; Peloquin, M.; Horvath, A.; Pap, A.; Daniel, B.; Nagy, G.; Pintye, E.; et al. Macrophage PPARγ, a Lipid Activated Transcription Factor Controls the Growth Factor GDF3 and Skeletal Muscle Regeneration. Immunity 2016, 45, 1038–1051. [Google Scholar] [CrossRef]
  95. Patsalos, A.; Halasz, L.; Oleksak, D.; Wei, X.; Nagy, G.; Tzerpos, P.; Conrad, T.; Hammers, D.W.; Sweeney, H.L.; Nagy, L. Spatiotemporal transcriptomic mapping of regenerative inflammation in skeletal muscle reveals a dynamic multilayered tissue architecture. J. Clin. Investig. 2024, 134, e173858. [Google Scholar] [CrossRef]
  96. Shang, M.; Cappellesso, F.; Amorim, R.; Serneels, J.; Virga, F.; Eelen, G.; Carobbio, S.; Rincon, M.Y.; Maechler, P.; De Bock, K.; et al. Macrophage-derived glutamine boosts satellite cells and muscle regeneration. Nature 2020, 587, 626–631. [Google Scholar] [CrossRef]
  97. Baht, G.S.; Bareja, A.; Lee, D.E.; Rao, R.R.; Huang, R.; Huebner, J.L.; Bartlett, D.B.; Hart, C.R.; Gibson, J.R.; Lanza, I.R.; et al. Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism. Nat. Metab. 2020, 2, 278–289, Erratum in Nat. Metab. 2020, 2, 794. [Google Scholar] [CrossRef]
  98. McArthur, S.; Juban, G.; Gobbetti, T.; Desgeorges, T.; Theret, M.; Gondin, J.; Toller-Kawahisa, J.E.; Reutelingsperger, C.P.; Chazaud, B.; Perretti, M.; et al. Annexin A1 drives macrophage skewing to accelerate muscle regeneration through AMPK activation. J. Clin. Investig. 2020, 130, 1156–1167. [Google Scholar] [CrossRef]
  99. Urciuolo, A.; Quarta, M.; Morbidoni, V.; Gattazzo, F.; Molon, S.; Grumati, P.; Montemurro, F.; Tedesco, F.S.; Blaauw, B.; Cossu, G.; et al. Collagen VI regulates satellite cell self-renewal and muscle regeneration. Nat. Commun. 2013, 4, 1964. [Google Scholar] [CrossRef] [PubMed]
  100. Joe, A.W.; Yi, L.; Natarajan, A.; Le Grand, F.; So, L.; Wang, J.; Rudnicki, M.A.; Rossi, F. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat. Cell Biol. 2010, 12, 153–163. [Google Scholar] [CrossRef] [PubMed]
  101. Uezumi, A.; Fukada, S.-I.; Yamamoto, N.; Takeda, S.; Tsuchida, K. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat. Cell Biol. 2010, 12, 143–152. [Google Scholar] [CrossRef] [PubMed]
  102. Uezumi, A.; Ikemoto-Uezumi, M.; Tsuchida, K. Roles of nonmyogenic mesenchymal progenitors in pathogenesis and regeneration of skeletal muscle. Front. Physiol. 2014, 5, 68. [Google Scholar] [CrossRef]
  103. Lemos, D.R.; Babaeijandaghi, F.; Low, M.; Chang, C.-K.; Lee, S.T.; Fiore, D.; Zhang, R.-H.; Natarajan, A.; A Nedospasov, S.; Rossi, F.M.V. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat. Med. 2015, 21, 786–794. [Google Scholar] [CrossRef]
  104. Wang, X.; Zhao, W.; Ransohoff, R.M.; Zhou, L. Identification and Function of Fibrocytes in Skeletal Muscle Injury Repair and Muscular Dystrophy. J. Immunol. 2016, 197, 4750–4761. [Google Scholar] [CrossRef]
  105. Fabre, T.; Barron, A.M.S.; Christensen, S.M.; Asano, S.; Bound, K.; Lech, M.P.; Wadsworth, M.H.; Chen, X.; Wang, C.; Wang, J.; et al. Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation. Sci. Immunol. 2023, 8, eadd8945. [Google Scholar] [CrossRef]
  106. Ramachandran, P.; Dobie, R.; Wilson-Kanamori, J.R.; Dora, E.F.; Henderson, B.E.P.; Luu, N.T.; Portman, J.R.; Matchett, K.P.; Brice, M.; Marwick, J.A.; et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 2019, 575, 512–518. [Google Scholar] [CrossRef]
  107. Ke, D.; Cao, M.; Ni, J.; Yuan, Y.; Deng, J.; Chen, S.; Dai, X.; Zhou, H. Macrophage and fibroblast trajectory inference and crosstalk analysis during myocardial infarction using integrated single-cell transcriptomic datasets. J. Transl. Med. 2024, 22, 560. [Google Scholar] [CrossRef] [PubMed]
  108. Emery, A.E.H. The muscular dystrophies. BMJ 1998, 317, 991–995. [Google Scholar] [CrossRef] [PubMed]
  109. Emery, A.E.H. Duchenne Muscular Dystrophy; Oxford University Press: Oxford, UK, 1993. [Google Scholar]
  110. Rando, T.A. The dystrophin–glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 2001, 24, 1575–1594. [Google Scholar] [CrossRef]
  111. Theret, M.; Saclier, M.; Messina, G.; Rossi, F.M. Macrophages in Skeletal Muscle Dystrophies, An Entangled Partner. J. Neuromuscul. Dis. 2022, 9, 1–23. [Google Scholar] [CrossRef]
  112. Goldspink, G.; Fernandes, K.; Williams, P.E.; Wells, D.J. Age-related changes in collagen gene expression in the muscles of mdx dystrophic and normal mice. Neuromuscul. Disord. 1994, 4, 183–191. [Google Scholar] [CrossRef]
  113. Hartel, J.V.; Granchelli, J.A.; Hudecki, M.S.; Pollina, C.M.; Gosselin, L.E. Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice. Muscle Nerve 2001, 24, 428–432. [Google Scholar] [CrossRef]
  114. Stedman, H.H.; Sweeney, H.L.; Shrager, J.B.; Maguire, H.C.; Panettieri, R.A.; Petrof, B.; Narusawa, M.; Leferovich, J.M.; Sladky, J.T.; Kelly, A.M. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991, 352, 536–539. [Google Scholar] [CrossRef]
  115. Beastrom, N.; Lu, H.; Macke, A.; Canan, B.D.; Johnson, E.K.; Penton, C.M.; Kaspar, B.K.; Rodino-Klapac, L.R.; Zhou, L.; Janssen, P.M.; et al. mdx((5)cv) mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx mice. Am. J. Pathol. 2011, 179, 2464–2474. [Google Scholar] [CrossRef] [PubMed]
  116. Dupont-Versteegden, E.E.; McCarter, R.J. Differential expression of muscular dystrophy in diaphragm versus hindlimb muscles of mdx mice. Muscle Nerve 1992, 15, 1105–1110. [Google Scholar] [CrossRef] [PubMed]
  117. Huang, P.; Cheng, G.; Lu, H.; Aronica, M.; Ransohoff, R.M.; Zhou, L. Impaired respiratory function in mdx and mdx/utrn+/− mice. Muscle Nerve 2011, 43, 263–267. [Google Scholar] [CrossRef]
  118. Wehling, M.; Spencer, M.J.; Tidball, J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol. 2001, 155, 123–132. [Google Scholar] [CrossRef]
  119. Juban, G.; Saclier, M.; Yacoub-Youssef, H.; Kernou, A.; Arnold, L.; Boisson, C.; Ben Larbi, S.; Magnan, M.; Cuvellier, S.; Théret, M.; et al. AMPK Activation Regulates LTBP4-Dependent TGF-β1 Secretion by Pro-inflammatory Macrophages and Controls Fibrosis in Duchenne Muscular Dystrophy. Cell Rep. 2018, 25, 2163–2176.e2166. [Google Scholar] [CrossRef] [PubMed]
  120. Madaro, L.; Torcinaro, A.; De Bardi, M.; Contino, F.F.; Pelizzola, M.; Diaferia, G.R.; Imeneo, G.; Bouchè, M.; Puri, P.L.; De Santa, F. Macrophages fine tune satellite cell fate in dystrophic skeletal muscle of mdx mice. PLoS Genet. 2019, 15, e1008408. [Google Scholar] [CrossRef] [PubMed]
  121. Saleh, K.K.; Xi, H.; Switzler, C.; Skuratovsky, E.; Romero, M.A.; Chien, P.; Gibbs, D.; Gane, L.; Hicks, M.R.; Spencer, M.J.; et al. Single cell sequencing maps skeletal muscle cellular diversity as disease severity increases in dystrophic mouse models. iScience 2022, 25, 105415. [Google Scholar] [CrossRef]
  122. Coulis, G.; Jaime, D.; Guerrero-Juarez, C.; Kastenschmidt, J.M.; Farahat, P.K.; Nguyen, Q.; Pervolarakis, N.; McLinden, K.; Thurlow, L.; Movahedi, S.; et al. Single-cell and spatial transcriptomics identify a macrophage population associated with skeletal muscle fibrosis. Sci. Adv. 2023, 9, eadd9984. [Google Scholar] [CrossRef]
  123. Hoeft, K.; Schaefer, G.J.; Kim, H.; Schumacher, D.; Bleckwehl, T.; Long, Q.; Klinkhammer, B.M.; Peisker, F.; Koch, L.; Nagai, J.; et al. Platelet-instructed SPP1+ macrophages drive myofibroblast activation in fibrosis in a CXCL4-dependent manner. Cell Rep. 2023, 42, 112131. [Google Scholar] [CrossRef] [PubMed]
  124. Hendrikx, T.; Porsch, F.; Kiss, M.G.; Rajcic, D.; Papac-Miličević, N.; Hoebinger, C.; Goederle, L.; Hladik, A.; Shaw, L.E.; Horstmann, H.; et al. Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. J. Hepatol. 2022, 77, 1373–1385. [Google Scholar] [CrossRef]
  125. Ouyang, J.F.; Mishra, K.; Xie, Y.; Park, H.; Huang, K.Y.; Petretto, E.; Behmoaras, J. Systems level identification of a matrisome-associated macrophage polarisation state in multi-organ fibrosis. eLife 2023, 12, e85530. [Google Scholar] [CrossRef]
  126. Morse, C.; Tabib, T.; Sembrat, J.; Buschur, K.L.; Bittar, H.T.; Valenzi, E.; Jiang, Y.; Kass, D.J.; Gibson, K.; Chen, W.; et al. Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur. Respir. J. 2019, 54, 1802441. [Google Scholar] [CrossRef]
  127. Palma, A. The Landscape of SPP1+ Macrophages Across Tissues and Diseases: A Comprehensive Review. Immunology 2025, 176, 179–196. [Google Scholar] [CrossRef]
  128. Tang, Z.; Xia, Z.; Wang, X.; Liu, Y. The critical role of osteopontin (OPN) in fibrotic diseases. Cytokine Growth Factor Rev. 2023, 74, 86–99. [Google Scholar] [CrossRef] [PubMed]
  129. Vetrone, S.A.; Montecino-Rodriguez, E.; Kudryashova, E.; Kramerova, I.; Hoffman, E.P.; Liu, S.D.; Miceli, M.C.; Spencer, M.J. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-β. J. Clin. Investig. 2009, 119, 1583–1594. [Google Scholar] [CrossRef]
  130. Farahat, P.K.; Kumagai-Cresse, C.; Aragón, R.L.; Ma, F.; Amakor, J.K.; Espinoza, A.; Kramerova, I.; Jimenez, R.J.; Smith, B.M.; Perez, J.; et al. Macrophage-derived Spp1 promotes intramuscular fat in dystrophic muscle. JCI Insight 2025, 10, e181946. [Google Scholar] [CrossRef] [PubMed]
  131. Cui, H.; Banerjee, S.; Xie, N.; Hussain, M.; Jaiswal, A.; Liu, H.; Kulkarni, T.; Antony, V.B.; Liu, R.-M.; Colonna, M.; et al. TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity. Nat. Commun. 2025, 16, 1761. [Google Scholar] [CrossRef]
  132. Gong, S.; Zhai, M.; Shi, J.; Yu, G.; Lei, Z.; Shi, Y.; Zeng, Y.; Ju, P.; Yang, N.; Zhang, Z.; et al. TREM2 macrophage promotes cardiac repair in myocardial infarction by reprogramming metabolism via SLC25A53. Cell Death Differ. 2024, 31, 239–253. [Google Scholar] [CrossRef]
  133. Huang, P.; Zhao, X.S.; Fields, M.; Ransohoff, R.M.; Zhou, L. Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J. 2009, 23, 2539–2548. [Google Scholar] [CrossRef]
  134. Huebner, K.D.; Jassal, D.S.; Halevy, O.; Pines, M.; Anderson, J.E. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H1550–H1561. [Google Scholar] [CrossRef]
  135. Spurney, C.F.; Sali, A.; Guerron, A.D.; Iantorno, M.; Yu, Q.; Gordish-Dressman, H.; Rayavarapu, S.; van der Meulen, J.; Hoffman, E.P.; Nagaraju, K. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient Mdx mice. J. Cardiovasc. Pharmacol. Ther. 2011, 16, 87–95. [Google Scholar] [CrossRef]
  136. Taniguti, A.P.T.; Pertille, A.; Matsumura, C.Y.; Neto, H.S.; Marques, M.J. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-β1 blocker. Muscle Nerve 2011, 43, 82–87. [Google Scholar] [CrossRef]
  137. Turgeman, T.; Hagai, Y.; Huebner, K.; Jassal, D.S.; Anderson, J.E.; Genin, O.; Nagler, A.; Halevy, O.; Pines, M. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul. Disord. 2008, 18, 857–868. [Google Scholar] [CrossRef] [PubMed]
  138. Capote, J.; Kramerova, I.; Martinez, L.; Vetrone, S.; Barton, E.R.; Sweeney, H.L.; Miceli, M.C.; Spencer, M.J. Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype. J. Cell Biol. 2016, 213, 275–288. [Google Scholar] [CrossRef] [PubMed]
  139. Villalta, S.A.; Rinaldi, C.; Deng, B.; Liu, G.; Fedor, B.; Tidball, J.G. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum. Mol. Genet. 2011, 20, 790–805. [Google Scholar] [CrossRef] [PubMed]
  140. Kourakis, S.; Timpani, C.A.; Campelj, D.G.; Hafner, P.; Gueven, N.; Fischer, D.; Rybalka, E. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? Orphanet J. Rare Dis. 2021, 16, 117. [Google Scholar] [CrossRef]
  141. Aoki, Y.; Miyatake, S.; Shimizu-Motohashi, Y.; Takeda, S. Anti-inflammatory drugs for Duchenne muscular dystrophy: Focus on skeletal muscle-releasing factors. Drug Des. Dev. Ther. 2016, 10, 2745–2758. [Google Scholar] [CrossRef]
  142. Guglieri, M.; Clemens, P.R.; Perlman, S.J.; Smith, E.C.; Horrocks, I.; Finkel, R.S.; Mah, J.K.; Deconinck, N.; Goemans, N.; Haberlova, J.; et al. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys with Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA Neurol. 2022, 79, 1005–1014. [Google Scholar] [CrossRef]
  143. Buchman, A.L. Side Effects of Corticosteroid Therapy. J. Clin. Gastroenterol. 2001, 33, 289–294. [Google Scholar] [CrossRef]
  144. Jang, Y.H.; Choi, E.-Y.; Lee, H.; Woo, J.; Park, S.; Noh, Y.; Jeon, J.-Y.; Yoo, E.-Y.; Shin, J.-Y.; Lee, Y.W. Long-Term Use of Oral Corticosteroids and Safety Outcomes for Patients with Atopic Dermatitis. JAMA Netw. Open 2024, 7, e2423563. [Google Scholar] [CrossRef]
  145. Mercuri, E.; Vilchez, J.J.; Boespflug-Tanguy, O.; Zaidman, C.M.; Mah, J.K.; Goemans, N.; Müller-Felber, W.; Niks, E.H.; Schara-Schmidt, U.; Bertini, E.; et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024, 23, 393–403, Erratum in Lancet Neurol. 2024, 23, e10. Erratum in Lancet Neurol. 2024, 23, e12. [Google Scholar] [CrossRef] [PubMed]
  146. Babaeijandaghi, F.; Kajabadi, N.; Long, R.; Tung, L.W.; Cheung, C.W.; Ritso, M.; Chang, C.-K.; Cheng, R.; Huang, T.; Groppa, E.; et al. DPPIV+ fibro-adipogenic progenitors form the niche of adult skeletal muscle self-renewing resident macrophages. Nat. Commun. 2023, 14, 8273. [Google Scholar] [CrossRef] [PubMed]
  147. Bellver-Landete, V.; Bretheau, F.; Mailhot, B.; Vallières, N.; Lessard, M.; Janelle, M.-E.; Vernoux, N.; Tremblay, M.; Fuehrmann, T.; Shoichet, M.S.; et al. Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury. Nat. Commun. 2019, 10, 518. [Google Scholar] [CrossRef]
  148. Montilla, A.; Zabala, A.; Er-Lukowiak, M.; Rissiek, B.; Magnus, T.; Rodriguez-Iglesias, N.; Sierra, A.; Matute, C.; Domercq, M. Microglia and meningeal macrophages depletion delays the onset of experimental autoimmune encephalomyelitis. Cell Death Dis. 2023, 14, 16. [Google Scholar] [CrossRef] [PubMed]
Ijms 27 01332 g001
Figure 1. Scheme showing the origins of adult skeletal muscle resident macrophages. TLF+ muscle resident macrophages are established during embryo development from both yolk sac and fetal liver hematopoiesis. They persist into adulthood through self-renewal. CCR2+MHCIIhi muscle resident macrophages are from adult bone marrow HSC-derived blood Ly6ChiCCR2+ monocytes. HSC: hematopoietic stem cell. MO: monocyte. MP: macrophage. TLF+: Timd4+ and/or Lyve1+ and/or Folr2+.
Figure 1. Scheme showing the origins of adult skeletal muscle resident macrophages. TLF+ muscle resident macrophages are established during embryo development from both yolk sac and fetal liver hematopoiesis. They persist into adulthood through self-renewal. CCR2+MHCIIhi muscle resident macrophages are from adult bone marrow HSC-derived blood Ly6ChiCCR2+ monocytes. HSC: hematopoietic stem cell. MO: monocyte. MP: macrophage. TLF+: Timd4+ and/or Lyve1+ and/or Folr2+.
Ijms 27 01332 g001
Ijms 27 01332 g002
Figure 2. Schematic summary of the heterogeneous activation of infiltrating monocytes/macrophages in acutely injured and dystrophic skeletal muscle. Evidence is still lacking whether pro-inflammatory macrophages can further differentiate into Gpnmb+/Spp1+ macrophages or not. IFNRM: interferon-responsive macrophage.
Figure 2. Schematic summary of the heterogeneous activation of infiltrating monocytes/macrophages in acutely injured and dystrophic skeletal muscle. Evidence is still lacking whether pro-inflammatory macrophages can further differentiate into Gpnmb+/Spp1+ macrophages or not. IFNRM: interferon-responsive macrophage.
Ijms 27 01332 g002
Table 1. Anti-inflammatory treatments in clinical use for DMD.
Table 1. Anti-inflammatory treatments in clinical use for DMD.
NameMechanismFDA approvalApplication
Prednisone [140]Synthetic glucocorticoidOff-label useStandard treatment
Deflazacort [140]Oxazoline derivative of prednisoloneApproved in 2017Patients aged 5 years and older
Vamorolone [140,142]Anti-inflammatory steroid analogueApproved in 2023Patients aged 2 years and older
Givinostat [145]Histone deacetylase (HDAC) inhibitor Approved in 2024Patients aged 6 years and older
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wang, X.; Zhou, L. Macrophage Infiltration, Activation, and Therapeutic Implication in Skeletal Muscle Injury and Repair. Int. J. Mol. Sci. 2026, 27, 1332. https://doi.org/10.3390/ijms27031332

AMA Style

Wang X, Zhou L. Macrophage Infiltration, Activation, and Therapeutic Implication in Skeletal Muscle Injury and Repair. International Journal of Molecular Sciences. 2026; 27(3):1332. https://doi.org/10.3390/ijms27031332

Chicago/Turabian Style

Wang, Xingyu, and Lan Zhou. 2026. "Macrophage Infiltration, Activation, and Therapeutic Implication in Skeletal Muscle Injury and Repair" International Journal of Molecular Sciences 27, no. 3: 1332. https://doi.org/10.3390/ijms27031332

APA Style

Wang, X., & Zhou, L. (2026). Macrophage Infiltration, Activation, and Therapeutic Implication in Skeletal Muscle Injury and Repair. International Journal of Molecular Sciences, 27(3), 1332. https://doi.org/10.3390/ijms27031332

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop